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Abstract
Epigenetics, or the reversible and heritable marks of gene regulation not including DNA sequence, encompasses chromatin
modifications on both the DNA and histones and is as important as the DNA sequence itself. Chromatin-modifying factors
are playing an increasingly important role in tumorigenesis, particularly among pediatric rhabdomyosarcomas (RMS),
revealing potential novel therapeutic targets. We performed an overexpression screen of chromatin-modifying factors in a
KRAS
G12D-driven zebrafish model for RMS. Here, we describe the identification of a histone H3 lysine 9 histone
methyltransferase, SUV39H1, as a suppressor of embryonal RMS formation in zebrafish. This suppression is specific to the
histone methyltransferase activity of SUV39H1, as point mutations in the SET domain lacked the effect. SUV39H1-
overexpressing and control tumors have a similar proliferation rate, muscle differentiation state, and tumor growth rate.
Strikingly, SUV39H1-overexpressing fish initiate fewer tumors, which results in the observed suppressive phenotype. We
demonstrate that the delayed tumor onset occurs between 5 and 7 days post fertilization. Gene expression profiling at
these stages revealed that in the context of KRAS
G12D overexpression, SUV39H1 may suppress cell cycle progression. Our
studies provide evidence for the role of SUV39H1 as a tumor suppressor.
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Introduction
Rhabdomyosarcoma (RMS) is a pediatric cancer representing
more than half of all soft tissue sarcomas in children. 350 new
cases arise each year in the United States, with two-thirds of those
occurring in children under the age of ten [1–3]. RMS tumors are
generally sporadic and tend to occur more frequently in boys than
girls [1]. The overall survival rate when including non-metastatic
cases is currently nearly 80%, as compared to only 25% in the
1970s [4]. This is likely due to advancements in molecular biology
techniques that allow for improved diagnosis and imaging, leading
to tailored therapies. However, in about 20% of cases, the disease
is metastatic at presentation, and even with aggressive treatments,
five-year survival rates hover around 20%, suggesting there is still
much to learn about the biology of RMS [1].
There are two main histological subtypes of RMS. The
embryonal RMS (ERMS) subtype consists of 80% of RMS cases,
is mainly in the pediatric population, and typically has a better
prognosis. ERMS is characterized by mutations or dysregulation
of the RAS pathway and loss of heterozygosity at BWR1A [5–10].
A transgenic model of ERMS has previously been developed in the
zebrafish, accomplished by driving expression of oncogenic human
KRAS
G12D with the rag2 promoter, which was shown to drive
expression in mononuclear muscle satellite cells. The fish begin
developing tumors as larvae and express the traditional clinical
markers of ERMS, including myogenin, myod, and desmin, equivalent
to the pediatric patients [5]. The alveolar subtype (ARMS) is more
likely to occur in adolescents, be metastatic, and have a poorer
prognosis. ARMS is caused by a chromosomal translocation
between either Pax3 or Pax7 and forkhead transcription factors
[1,8,11].
Though little is known about the role of chromatin-modifying
factors in RMS, several studies have implicated components of the
Polycomb Group and SWI/SNF chromatin remodeling complex.
Polycomb Group member YY1 was found to be upregulated in
RMS cell lines and primary tumors, thus leading to recruitment of
EZH2 and HDAC1 to miR-29, silencing this microRNA, and
thereby preventing muscle differentiation and facilitating tumor
development [12]. Human SNF5 homolog, BAF47, was noted to
be mutated or deleted in 25% of primary tumors and 10% of
RMS cell lines analyzed [13,14]. Upon treatment with 12-O-
Tetradecanoylphorbol-13-acetate (TPA), the ERMS cell line RD
differentiates through a mechanism involving PCAF and the
BRG1 subunit of the SWI/SNF complex being sequentially
recruited to the myogenin promoter, representing a novel therapeu-
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factors may also represent useful diagnostic markers or novel drug
targets in RMS. For instance, the histone demethylase LSD1 was
shown to have high expression levels in malignant sarcomas,
including ARMS (2/2) and ERMS (6/7) tumors; it may prove
useful as a diagnostic marker or a novel drug target [16,17]. Since
the regulation of chromatin structure can play a determinative role
in the formation and behavior of cancers of the muscle, it is likely
that many more chromatin factors participate in RMS but remain
to be discovered.
Here, we used an injection-based screening approach in
zebrafish to interrogate the role of nineteen chromatin-modifying
factors in RMS formation. We identified histone methyltransferase
SUV39H1 as a strong suppressor of RMS formation, and this
effect was dependent on an active SET domain. While SUV39H1
did not impact overall tumor characteristics when compared to
control tumors, including histological and gene expression
analyses, studies of tumor initiation using a fluorescent monitoring
system demonstrated that SUV39H1 acts between 5 and 7 days
post fertilization (dpf) to delay the onset of tumor formation. Gene
expression studies also demonstrate a potential cell cycle regulation
defect in SUV39H1 injected embryos. This data suggests a model
in which altered cell cycle regulation caused by SUV39H1
overexpression is responsible for the decrease in RMS tumor
initiation.
Methods
Zebrafish
Zebrafish were maintained and developmentally staged as
previously described according to IACUC guidelines [18]. The
Animal Care and Use Committee, Children’s Hospital Boston
approved all animal protocols.
Vectors and cloning
The rag2-hKRAS
G12D and rag2-GFP vectors were previously
described [5]. The mylz2-GFP and mCherry vectors were
previously described [19]. To create the rag2 destination vector,
the rag2-hKRAS
G12D vector was digested with BamHI and
HindIII, blunt-ended with Klenow, incubated with Shrimp
Alkaline Phosphatase and purified; the rag2 destination vector
for Gateway cloning was then constructed from the blunt-ended
vector using the Gateway Vector Conversion System (Invitrogen,
Life Technologies, Grand Island, NY). rag2-hSUV39H1
H324K and
rag2-hSUV39H1
C326A vectors were obtained from C. Ceol [20].
rag2-chromatin factor expression vectors were generated by
Gateway recombination using human, full-length open reading
frames from the Ultimate ORF Clone collection (Invitrogen, Life
Technologies, Grand Island, NY). A pENTR-mPAX7 vector was
obtained from Open Biosystems (Thermo Fisher Scientific,
Huntsville, AL) and was put behind the rag2 promoter through
Gateway recombination. All constructs were sequence verified.
Microinjection and tumor scoring
The rag2-hKRAS
G12D, rag2-chromatin factor, and all fluores-
cent protein/SUV39H1-containing vectors were linearized with
XhoI, purified, and diluted in 0.56TE+0.1 M KCl. For co-
injection of three transgenes, each was diluted to 40 ng/uL, and
for co-injection of four transgenes, each was diluted to 30 ng/uL.
One nL of the vector dilutions was microinjected into the nucleus
of one-cell stage AB strain zebrafish embryos. For the screen, fish
were scored for visible tumor formation every 2–4 days
commencing at 12 dpf. For younger larvae, fish were scored for
tumor formation by presence of fluorescence every 2–3 days
commencing at 6 dpf. For the tumor growth analysis, fluorescent
photos of each fish were taken at the same zoom and
magnification, and photos were analyzed for number of fluores-
cent pixels on ImageJ.
Identification of known and putative chromatin
modifying factors
Human chromatin modifying factors were identified using
CREMOFAC, SMART domain, CDD, and Pfam databases.
Gene set enrichment analysis
GSEA on published human microarray data sets was performed
as described previously [5,21].
Statistical analysis
Tumor-free survival over time is graphically represented as a
Kaplan-Meier estimate of survival using GraphPad Prism (La
Jolla, CA). The log-rank test was used to compare survival of
experimental and control groups.
Microarray analysis
RNA was isolated at 5 and 7 dpf from approximately twenty
sibling embryos per sample, with three biological replicates, for
each of the rag2-mCherry and rag2-hSUV39H1 types with the
RNeasy Mini Kit (Qiagen, Valencia, CA) using the animal tissue
protocol and subsequently treated with DNase I. cDNA was
prepared and hybridized to zebrafish Affymetrix arrays according
to manufacturer’s instructions. Genes differentially regulated
between the tumor types were identified (.2-fold change,
p,0.05).
EdU incorporation
Tumor-bearing fish at 28 to 30 dpf were injected intraperito-
neally with 10 ul of 2.5 mg/ml EdU per 0.25 g body weight. After
24 hours, fish were euthanized and frozen in Optimal Cutting
Temperature (OCT) medium at 280uC overnight. 12 um cryostat
sections were prepared for each tumor, and EdU labeling was
performed using the Click-iT EdU Alexa Fluor 594 Imaging Kit
(Invitrogen, Life Technologies, Grand Island, NY). Labeled
sections were imaged at 4006 magnification using a compound
fluorescent microscope, and the number of EdU-positive and
DAPI-positive nuclei were counted in three separate
1.37610
4 um
2 fields per tumor. The ratios of EdU-positive to
DAPI-positive nuclei in the three fields were averaged to calculate
an EdU/DAPI ratio for each tumor.
Histopathology
Fish were euthanized and fixed in 4% paraformaldehyde
overnight at 4uC and then decalcified in 0.5 M EDTA, pH8.
Paraffin embedding, sectioning, and H&E staining were per-
formed according to standard techniques by the Brigham &
Women’s Pathology Core.
TUNEL staining
Staining for TUNEL was completed on sections of 5 and 7 dpf
highly mosaic larvae injected with rag2-hKRAS
G12D, rag2-
hSUV39H1 or mCherry, and mylz2-GFP. Larvae were fixed in
4% paraformaldehyde (PFA) overnight, bleached to remove
melanocytes in a 3% H2O2/0.5% KOH solution for 45 minutes,
then fixed again overnight in 4% PFA. Following paraffin
embedding and sectioning, larvae sections were then stained
according to manufacturer’s instructions using the ApopTagH Plus
Peroxidase In Situ Apoptosis Kit (Millipore, Billerica, MA).
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counted in two separate musculature fields in five larvae of each
injected type.
Quantitative RT-PCR
For analysis of larvae, RNA was isolated at 7dpf from 12 sibling
larvae per sample, 3 samples total, for each of the rag2-mCherry
and rag2-hSUV39H1 types with the RNeasy Mini Kit (Qiagen,
Valencia, CA) and treated with DNaseI. For tumor analysis, RNA
was isolated at ,30dpf from five tumors (one tumor per sample)
for each of the rag2-mCherry and rag2-hSUV39H1 types using
TRIzol reagent (Invitrogen), treated with DNase I, and purified
using the RNeasy Mini Kit (Qiagen). cDNA synthesis was
performed from equal quantities of RNA using SuperScript III
First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen), and
quantitative RT-PCR was performed using SYBR GreenER
qPCR SuperMix for iCycler (Invitrogen) on a BioRad C1000
Thermal Cycler. Primers used for QPCR are included in Table
S1. For each sample, relative gene expression was calculated from
experimental triplicates using the 2
2DDCT method, with normal-
ization to EF1-alpha transcript levels within each sample.
Normalized relative gene expression was then averaged across
samples for each group, and gene transcript expression levels
between rag2-mCherry and rag2-hSUV39H1 types were compared
using the student’s t-test.
Results
An in vivo overexpression screen in zebrafish to identify
modifiers of embryonal rhabdomyosarcoma
To identify chromatin-modifying factors that act as modifiers of
RMS, we utilized a previously characterized model of ERMS in
the zebrafish [5]. This model was based on a microinjection
strategy amenable to co-injection of different factors with their
expression driven by the rag2 promoter. Injection of a rag2-
hKRAS
G12D construct drives tumor formation; additional genes
on separate, linearized plasmids are also driven by rag2 and co-
integrate with and are co-expressed in the rag2-hKRAS
G12D
tumors [5,22]. Therefore, we developed a strategy to identify
suppressors or enhancers of RMS formation when the candidate
gene, driven by rag2, was co-injected with rag2-hKRAS
G12D.T o
control for injection variability, a third construct, mylz2 (myosin light
polypeptide 2)-GFP, was co-injected. This allowed the microinjected
embryos to be separated into categories of mylz2-GFP-low, middle,
and high mosaicism at 2 dpf. The level of GFP mosaicism directly
correlated with successful microinjection of the hKRAS
G12D and
therefore tumor formation (data not shown). Those with high GFP
mosaicism were selected and visually analyzed for tumor
formation every 3 days from 12 to 50 dpf (Figure 1A).
We developed a list of chromatin factors to test for enhance-
ment or suppression of RMS based on domains identified by
various databases (list of domains shown in Figure S1A); any gene
containing one or more of these domains was considered to be a
chromatin-modifying factor. Using gene set enrichment analysis
(GSEA) on human RMS microarray data sets, we found that this
list of putative or known chromatin modifiers was significantly
upregulated in human ERMS and ARMS (p,0.05, Figure
S1B,C). We also searched for particularly families of chromatin
factors to test. A total of nineteen human factors were chosen for
analysis, including ten that represent two important classes of
chromatin-modifying factors (SET or chromo domain proteins),
and ten of the most highly upregulated genes in human ERMS
versus normal muscle (Figure S1D; Figure S2). Of these factors,
SUV39H1 emerged as the strongest modifier, significantly
suppressing tumor formation from 12 dpf by the logrank test
(p=0.0001, Figure 1B).
Suppression by SUV39H1 occurs early and is dependent
on methyltransferase activity
SUV39H1-overexpressing tumors had a delay in tumor onset,
so the Kaplan-Meier curve appears suppressed from the beginning
of the assay at 12 dpf. To examine tumor formation with a more
sensitive and quantitative assay, we used a quantitative fluorescent
assay with a quadruple injection approach. As before, zebrafish
were injected with rag2-hKRAS
G12D and either rag2-hSUV39H1
or, as a control, rag2-mCherry. The third construct was rag2-GFP
to track the tumors by fluorescence as they arose, as it has been
shown that 100% of rag2-GFP-positive foci go on to eventually
form a tumor [23]. This enabled us to begin to see tumors days
earlier than by the naked eye alone, thus resulting in shifted tumor
curves relative to Figure 1B. The fourth construct was mylz2-
mCherry to continue analyzing only successfully microinjected
embryos, scored in 2 dpf embryos as for the screen. The inclusion
of rag2-mCherry as a control did not interfere with the ability to
score injections due to the timing difference in expression, since
the rag2 promoter turns on several days later. Because we track
tumor formation with rag2-GFP, our control for rag2-SUV39H1,
rag2-mCherry, does not confound our experimental results. By
analyzing GFP fluorescence in the musculature of highly mCherry
mosaic larvae, SUV39H1 still significantly suppressed RMS
formation at 20 dpf (p=0.0003, Figure 2A).
To determine if the histone methyltransferase (HMT) activity of
SUV39H1 played a role in tumor suppression, we utilized
SUV39H1 constructs with point mutations in the enzymatic
SET domain that have been shown to lack methyltransferase
activity [24]. We co-injected the SUV39H1 H324K and C326A
mutants along with rag2-hKRAS
G12D, rag2-GFP, and mylz2-
mCherry and analyzed early tumor formation by fluorescence.
Expression of either point mutant resulted in tumor-free survival
curves similar to the control mCherry-overexpression curve rather
than the suppressed SUV39H1-overexpression curve (C326A
p=0.0525, H324K p=0.7642, Figure 2B,C). This result indicates
that the tumor suppression by SUV39H1 depends on the HMT
activity of the SET domain in SUV39H1, ruling out primarily
scaffold effects since this enzyme is a part of a multiprotein
complex.
Characterization of SUV39H1-overexpressing tumors
Since SUV39H1 is known to play a role in regulation of cell
cycle and S phase genes [25–28], we investigated whether there
was any difference in cell cycle rate between SUV39H1-
overexpressing tumors and control tumors overexpressing
mCherry. 5-ethynyl-29-deoxyuridine (EdU), a bromodeoxyuridine
analog, was injected intraperitoneally into five 30 dpf fish of each
tumor type. Twenty-four hours post injection, the fish were
sacrificed, embedded in OCT, and cryosectioned (Figure 3A).
Staining for EdU in GFP-positive tumor sections revealed no
difference in the percentage of cells dividing during labeling when
normalized to cell number by DAPI staining, indicating no
difference in cell cycle rate in the SUV39H1-overexpressing and
control tumors (Student’s t-test, p=0.78, Figure 3B).
We wondered if muscle differentiation may be affected in the
SUV39H1-expressing tumors, since SUV39H1 is known to
regulate the master muscle regulator MyoD [29]. H&E staining
on SUV39H1 and control tumors revealed no obvious changes in
muscle differentiation status at the gross histologic level. Both sets
of tumors were in an undifferentiated state, with higher cellularity
and mostly mononucleated cells (Figure 3C). Global gene
SUV39H1 Suppresses Zebrafish Rhabdomyosarcoma
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identify major differences (Figure S3). These studies demonstrate
that overexpression of SUV39H1 did not significantly affect cell
cycle rate or the differentiation state of rag2-hKRAS
G12D RMS
tumors, at least at the gross histological level.
SUV39H1 suppresses RMS tumor initiation
The suppressive phenotype of SUV39H1 tumors in the Kaplan-
Meier survival curves has already occurred at the first time point of
12 dpf (Figure 1C). To examine the earliest changes underlying
this tumor suppression, we utilized the quadruple co-injection
approach described above and shown in Figure 2. At 7 dpf, highly
mCherry mosaic larval fish were examined for the presence of
GFP in the musculature. Those that had GFP positive cells at 7
dpf were examined again at 10 and 13 dpf for the growth of these
fluorescent patches into tumors (Figure 4A). In 100% of cases, the
GFP-positive patches went on to produce a tumor, some even
during this early time period examined (Figure 4B). The size of the
developing tumors was quantified by measuring the number of
fluorescent pixels in the image using the image analysis software
ImageJ. Relative growth rates for SUV39H1 and control cohorts
revealed that both sets of tumors grew at the same rate (Student’s
t-test, p=0.46, Figure 4C). Within clutches containing equivalent
levels of mCherry mosaicism, the number of larvae in a given
clutch with GFP-positive patches was evaluated in the muscula-
ture. Significantly fewer patches were found in the SUV39H1-
overexpression clutches compared to controls at 7 days (Fisher’s
exact test, p,0.0001, Figure 4D). This study in larvae demon-
strated that SUV39H1 overexpression impacts the initiation of
tumors. TUNEL analysis on 7 dpf larval sections revealed no
differences in apoptotic levels between SUV39H1 and control
larvae (p=0.26, Student’s t-test, Figure S4), eliminating increased
cell death as the cause of reduced tumor initiation. Our data
indicate that SUV39H1 overexpression affects the initiation of
tumors, but once the tumor initiates, it grows at the same rate as
control tumors.
As Figure 4 demonstrates, there is already a significant
difference between control and SUV39H1-overexpressing tumors
at 7 dpf. However, rag2-GFP fluorescence is rarely visualized at 5
dpf, suggesting that the first tumors initiate between 5 and 7 dpf.
To reveal what factors SUV39H1 could be repressing in the
initiation of RMS, we performed global gene expression analysis
on 5 and 7 dpf rag2-hKRAS
G12D, rag2-hSUV39H1/mCherry
embryos highly mosaic for mylz2-mCherry. As expected, the 5 dpf
SUV39H1-overexpressing larvae revealed no differences com-
pared to mCherry controls (data not shown). The 7 dpf larvae
Figure 1. An overexpression screen reveals SUV39H1 as a suppressor of rhabdomyosarcoma formation in zebrafish. (A) Three
linearized DNA constructs were injected into one-cell stage embryos, rag2-hKRAS
G12D, rag2-chromatin factor, and mylz2-GFP. At 2 dpf, embryos were
scored for GFP mosaicism; only those that were GFP-high were kept for tumor evaluation. Tumor-free survival curves were then constructed for days
12–50 of life, looking for enhancers or suppressors of tumor formation compared to control injected zebrafish with rag2-hKRAS
G12D without a
modifier gene. (B) SUV39H1 significantly suppressed RMS formation, compared to a control curve where the modifier gene was dsRed (SUV39H1
n=73, dsRed n=80, p=0.0001).
doi:10.1371/journal.pone.0064969.g001
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overexpressing and control fish (top genes shown in Figure 5A). Of
particular note is that cyclin B1 is downregulated in the
SUV39H1-expressing fish (Figure 5A). Follow-up with 7 dpf
larvae confirmed that cyclin B1 is indeed downregulated in
SUV39H1-overexpressing larvae compared with control larvae,
with the level of downregulation approaching significance
(p=0.0553, Figure 5B); additionally, this downregulation persists
as the tumors mature, as tumors from 30 dpf SUV39H1-
overexpressing fish demonstrated significantly lower levels of
cyclin B1 compared with control fish (p=0.0035, Figure S3).
Similarly, Ingenuity Pathway Analysis of the top up- and down-
regulated genes reveals that cyclins, polo-like kinase, and other cell
cycle regulators are among the top canonical pathways differen-
tially expressed in the SUV39H1-overexpressing fish (Figure 5C).
This suggests that one role of SUV39H1 in the tumorigenic
program is to suppress cell cycle entry.
Figure 2. Suppression by SUV39H1 depends on enzymatic SET domain. (A) Injections into one-cell stage embryos of rag2-hKRAS
G12D, rag2-
hSUV39H1, rag2-GFP, and mylz2-mCherry, then selected for mCherry-high embryos, and monitored for tumor formation by GFP presence, results in a
tumor-free survival curve that is significantly suppressed compared to the rag2-mCherry control curves. (SUV39H1 n=56, mCherry n=58, p=0.0003).
(B) Injection of the point mutant SUV39H1
C326A results in a tumor curve not significantly different from the mCherry control curve. However, this
curve is significantly different from rag2-hSUV39H1 tumors (C326A n=57, mCherry n=48, p=0.0525). (C) Similar injections of the rag2-
hSUV39H1
H324K point mutant also results in a tumor curve like the rag2-mCherry curve and significantly different from the rag2-hSUV39H1 curve
(H324K n=17, mCherry n=19, p=0.7642).
doi:10.1371/journal.pone.0064969.g002
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Chromatin-modifying factors have increasingly been found to
play an important role in tumorigenesis, particularly among
pediatric rhabdomyosarcomas. Here, we describe an overexpres-
sion screen of chromatin-modifying factors that revealed
SUV39H1 suppresses the onset of rhabdomyosarcoma formation
in zebrafish. This effect is specific to the histone methyltransferase
activity of SUV39H1, as point mutations in the SET domain
lacked the suppressive effect. We have demonstrated that the
effects are not simply due to SUV39H1 directly suppressing
KRAS
G12D expression, as oncogenic KRAS mRNA levels do not
significantly differ between SUV39H1-overexpressing and control
larvae and tumors. While the SUV39H1-overexpressing mature
tumors do not display differences in tumor proliferation and
muscle differentiation status, our studies establish that larval fish
with ectopic SUV39H1 expression initiate fewer tumors.
The requirement for the wild-type SET domain in our model is
striking since this was not the case of HMTs in a zebrafish
Figure 3. SUV39H1 overexpression does not impact cell cycle or muscle differentiation status of mature tumors. (A) Experimental
design for in vivo cell cycle analysis. One-cell stage embryos were injected with three constructs rag2-hKRAS
G12D, either rag2-mCherry or rag2-
hSUV39H1, and mylz2-GFP. High-GFP expressing fish were raised to 30 dpf, and those with tumors were injected IP with EdU. After 24 hours, the
injected fish were sacrificed and cryopreserved. (B) Number of EdU-positive cells, stained on GFP-positive tumor sections, was normalized to number
of total cells, determined by presence of DAPI. No difference was observed between the control and SUV39H1 tumors (n=5 for each group; p=0.78).
(C) H&E staining of RMS tumors overexpression either mCherry or SUV39H1. Both sets of tumors are very poorly differentiated; they also look similar
to each other, indicating no difference in differentiation state of the tumors (bars represent 50 um, n=6 for each group).
doi:10.1371/journal.pone.0064969.g003
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melanoma, two methyltransferase-deficient SETDB1 mutants also
had an accelerated tumor incidence curve, likely because the
complex still had methyltransferase activity [20]. This suggests that
RMS formation is more sensitive than melanoma formation to the
loss of SUV39H1 methyltransferase activity. It also suggests that
the suppressive phenotype of wild-type SUV39H1 overexpression
is not caused by a scaffold or dominant negative effect.
Global gene expression analysis comparing rag2-hKRAS
G12D/
rag2-hSUV39H1 with rag2-hKRAS
G12D/rag2-mCherry 7dpf lar-
vae revealed that cyclin B1 is downregulated in the SUV39H1-
overexpressing tumors, which was confirmed by qPCR.
SUV39H1 is already known to silence cyclins E and A [30].
Silencing of cyclin B1 may explain how SUV39H1 promotes
senescence and growth arrest. Quiescence can often be mediated
by cyclin B1 downregulation, as in CD34-negative hematopoietic
stem cells and quiescent NIH3T3 cells [31,32]. Sp1, a cell growth
and survival transcription factor, has been shown to associate with
SUV39H1 upon hydrogen peroxide treatment in an epithelial
carcinoma cell line, leading to growth arrest through the silencing
of Sp1 target genes, including cyclin B1 [33]. SUV39H1
overexpression may silence cyclin B1, leading to growth arrest
and decreased tumor initiation.
Previous studies involving SUV39H1 have demonstrated its role
as a tumor suppressor involving cell cycle regulation. SUV39H1
has been shown to impact the cell cycle through regulation of
Figure 4. SUV39H1 impacts the initiation, not the growth rate, of the tumors. (A) Experimental design to view the tumors in larval stages by
fluorescence. Four constructs are injected into one cell stage embryos, rag2-hKRAS
G12D, rag2-hSUV39H1 or control rag2-mCherry, rag2-GFP, and
mylz2-mCherry. Fish highly mosaicism for mylz2-mCherry expression are analyzed on day 7 for presence of GFP, indicative of developing tumors.
Analysis is also performed on day 10 to note tumor growth. (B) Representative images of 7 and 10 dpf larvae with GFP-positive cells in the
musculature. There is visible growth between 7 and 10 dpf as they develop into tumors. (C) Tumor growth rates, relative to size of tumor on day 7.
There is no significant difference between growth rates of the SUV39H1-overexpressing tumors compared to control tumors (SUV39H1 n=22,
mCherry n=13, p=0.46). (D) Percentage of larvae within a clutch that contain GFP-positive cells in the musculature. More fish in the mCherry
clutches have developing tumors when compared to SUV39H1 clutches (SUV39H1 n=200, mCherry n=136, p,0.0001).
doi:10.1371/journal.pone.0064969.g004
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PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e64969Figure 5. Global gene expression analysis reveals SUV39H1 may act through aberrant cell cycle regulation. (A) Table of top up- and
downregulated annotated genes in rag2-KRAS
G12D, rag2-SUV39H1 7 dpf larvae as compared to rag2-KRAS
G12D, rag2-mCherry control larvae. Of
particular interest was cyclin B1. (B) Gene expression analysis by qPCR in rag2-KRAS
G12D, rag2-SUV39H1 7 dpf larvae as compared to rag2-KRAS
G12D,
rag2-mCherry control larvae, all mylz2-GFP positive. Cyclin B1 downregulation was approaching significance, confirming the microarray analysis
(p=0.0553). As expected, SUV39H1 levels differ between the larvae, but KRAS levels do not, suggesting SUV39H1 is not simply downregulating KRAS
to suppress tumor formation (SUV39H1 p,0.0001; KRAS p=0.1284). SUV39H1 may also have an impact on some muscle differentiation genes at this
stage of tumor development (pax7 p=0.0230; myf5 p=0.0143; cdh15 p=0.0922; myog p=0.0017; desm p=0.4098; mylz2 p=0.1311). (C) Ingenuity
Pathway Analysis of top canonical pathways affected based on the 7 dpf microarray list. Of the top five pathways impacted, two involve cell cycle
regulators.
doi:10.1371/journal.pone.0064969.g005
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well as HDAC1, and a senescence response in melanocytes that
acts through these two proteins is mediated by SUV39H1
heterochromatization [30,34,35]. In a murine model of Ras-
driven T cell lymphoma, SUV39H1-dependent senescent growth
arrest prevents the onset of tumorigenesis; this senescence is likely
dependent on H3K9 methylation on specific growth genes [36].
Additionally, loss of SUV39H1 in Rb heterozygote mice leads to
the development of C cell adenocarcinomas, along with frequent
expression of proliferation markers, suggesting that SUV39H1
suppresses tumors through senescence [37]. When oncogenic
NRAS was transduced into cell lines derived from Rb deficient
tumors, senescence was induced and SUV39H1 was recruited to
chromatin [37]. Loss of SUV39H1 in a myc-driven model of
murine B cell lymphomas led to faster onset of disease, whereas
SUV39H1 wild-type mice displayed increased levels of senescence
and growth arrest [38]. It has been suggested that the SUV39H1-
mediated H3K9me3 mark on heterochromatin is a widespread
mark of the senescence program and that this program could be
targeted for cancer therapies [38].
As a cell cycle regulator, SUV39H1 is also known to silence S
phase genes as well as p21, both of which will induce growth arrest
[25–28,39]. SUV39H1 has been shown to associate with pRb in the
context of keeping E2F and its cell cycle-promoting target genes are
repressed through heterochromatization. SUV39H1 is phosphory-
lated at the G1/S transition to reduce its activity and allow for cell
cycle promotion;when overexpressed, ithas been shown tosuppress
cell growth. The identification of SUV39H1 as a suppressor of
RMS onset in our zebrafish model supports these studies and the
notion that SUV39H1 functions as a tumor suppressor [36,40].
With SUV39H1 as a potential tumor suppressor in RMS, we
looked to the Oncomine database to evaluate the status of
SUV39H1 expression in human RMS. According to the Khan
Multi-cancer study, SUV39H1 expression is down in RMS,
including both ERMS and ARMS subtypes, compared to skeletal
muscle tissue samples. This is consistent with our study, where
overexpression leads to reduced tumor formation. Therefore,
future research should investigate the pathways that SUV39H1
regulates in its role as a tumor suppressor, with particular focus on
cell cycle regulation. It also suggests that SUV39H1 may represent
a putative therapeutic target, whereby increasing SUV39H1
expression may block cell cycle progression and halt tumor
formation.
In conclusion, we performed a screen of chromatin-modifying
factors for their effects on tumorigenesis in RMS using zebrafish as
a model organism. Our screen revealed that chromatin-modifying
factors do play a role in RMS formation. SUV39H1 was
determined to be a suppressor of RMS formation, dependent on
its histone methyltransferase activity, suppressing tumor initiation
likely regulation of the cell cycle.
Supporting Information
Figure S1 Human RMS samples contain upregulation of
chromatin-modifying factors. (A) List of protein domains
resulting in a list of chromatin-modifying factors. (B) Gene set
enrichment analysis results show significant enrichment for
chromatin factor gene lists in human embryonal RMS versus
normal human juvenile muscle. (C) Gene set enrichment analysis
results show significant enrichment for chromatin factor gene lists
in human alveolar RMS versus normal human juvenile muscle
(p,0.05 for B,C). (D) List of twenty chromatin-modifying factors
screened for effects on RMS formation.
(TIF)
Figure S2 Screen of twenty chromatin-modifying fac-
tors for their role in rhabdomyosarcoma formation.
Twenty chromatin-modifying factors were analyzed for their
effects on RMS formation. Most did not result in significant
differences from the four historical control curves (dsRed).
(TIF)
Figure S3 SUV39H1 overexpression leads to downregu-
lation of cyclin B1 expression in mature tumors but does
not affect markers of muscle differentiation. Gene
expression analysis of tumors from rag2-hKRAS
G12D, rag2-
mCherry, and mylz2-mCherry-positive 30 dpf fish and rag2-
hKRAS
G12D, rag2-SUV39H1, and mylz2-mCherry-positive 30 dpf
fish. The only gene tested with a significant difference between
SUV39H1-overexpressing and control tumors was cyclin B1
(ccnb1, p=0.0035), though SUV39H1 was nearly significant, as
expected (p=0.0533). The remaining genes had no differences
between SUV39H1-overexpressing and control tumors, suggesting
that neither KRAS levels nor muscle differentiation were the cause
of tumor suppression (KRAS p=0.5855; pax7 p=0.5502; myf5
p=0.1103; cdh15 p=0.7720; myog p=0.8831; desm p=0.8739;
mylz2 p=0.2425).
(TIF)
Figure S4 SUV39H1 overexpression does not lead to
increased apoptosis. (A) TUNEL staining of rag2-
hKRAS
G12D, rag2-mCherry, and mylz2-mCherry-positive 7 dpf
fish (206). (B) Similar levels of cell death are seen in rag2-
hKRAS
G12D, rag2-hSUV39H1, and mylz2-mCherry-positive 7 dpf
fish, as noted by TUNEL staining (206). (C) Average number of
TUNEL-positive cells over two separate fields of musculature per
larvae (n=5 for each). This result reveals that there is not
increased apoptosis in the SUV39H1-overexpressing larvae,
suggesting the tumor initiating cells are not simply dying off
(p=0.26).
(TIF)
Table S1 List of primer sequences used for quantitative
RT-PCR.
(DOCX)
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